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The brain circuits underlying tics in Tourette's syndrome (TS) are unknown but thought to
involve cortico/amygdalo-striato-thalamo-cortical (CSTC) loop hyperactivity. We pre-Available online 8 October 2015
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viously engineered a transgenic mouse "circuit model" of TS by expressing an artiﬁcial
neuropotentiating transgene (encoding the cAMP-elevating, intracellular A1 subunit of
cholera toxin) within a small population of dopamine D1 receptor-expressing somatosen-
sory cortical and limbic neurons that hyperactivate cortico/amygdalostriatal glutamatergic
output circuits thought to be hyperactive in TS and comorbid obsessive–compulsive (OC)
disorders. As in TS, these D1CT-7 ("Ticcy") transgenic mice's tics were alleviated by the TS
drugs clonidine and dopamine D2 receptor antagonists; and their chronic glutamate-
excited striatal motor output was unbalanced toward hyperactivity of the motoric direct
pathway and inactivity of the cataleptic indirect pathway. Here we have examined
whether these mice's tics are countered by drugs that "break" sequential elements of2
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b r a i n r e s e a r c h 1 6 2 9 ( 2 0 1 5 ) 3 8 – 5 3 39their hyperactive cortical/amygdalar glutamatergic and efferent striatal circuit: anti-
serotonoceptive and anti-noradrenoceptive corticostriatal glutamate output blockers (the
serotonin 5-HT2a,c receptor antagonist ritanserin and the NE alpha-1 receptor antagonist
prazosin); agmatinergic striatothalamic GABA output blockers (the presynaptic agmatine/
imidazoline I1 receptor agonist moxonidine); and nigrostriatal dopamine output blockers
(the presynaptic D2 receptor agonist bromocriptine). Each drug class alleviates tics in the
Ticcy mice, suggesting a hyperglutamatergic CSTC "tic circuit" could exist in TS wherein
cortical/amygdalar pyramidal projection neurons' glutamatergic overexcitation of both
striatal output neurons and nigrostriatal dopaminergic modulatory neurons unbalances
their circuit integration to excite striatothalamic output and create tics, and illuminating
new TS drug strategies.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. CSTC hyperactivity and glutamate in TS and OCD
Tourette's syndrome (TS) is voluntarily suppressible, urge-
driven motor and/or vocal tics and repeated complex move-
ments, more prevalent and severe in males than females, and
often childhood-onset (Robertson, 2000) and comorbid with
obsessive–compulsive disorder (OCD), including the OC-
spectrum hair and skin picking disorders trichotillomania
(TTM) and dermatillomania (DTM) (American Psychiatric
Association, 2013), suggesting these comorbid syndromes
involve overlapping or parallel brain circuits.
A role for cortical and amygdalar glutamatergic output
neurons in eliciting and/or mediating neurogenic tics and
compulsions has been proposed (Campbell et al., 1999a, 1999b;
McGrath et al., 2000; Carlsson, 2000; Rosenberg et al., 2000;
Nordstrom and Burton, 2002; Singer et al., 2010; Milad and
Rauch, 2012). Functional MRI of TS shows primary hyperactivity
of excitatory somatosensory, insular and efferent motor output
circuits, which elicits premonitory urges and tics (Bohlhalter
et al., 2006; Wang et al., 2011), and secondary hypoactivity of
motor-suppressing executive-control circuits (Swerdlow and
Sutherland, 2005). The latter may include depleted or deﬁcient
regulatory interneuron populations, including not only cortical
inhibitory interneurons but striatal cholinergic interneurons that
normally excite striatal "indirect pathway" (IP) medium spiny
neurons (MSN) that suppress tics and compulsions, and striatal
parvalbumin-positive GABAergic fast-spiking interneurons (FSI)
that normally inhibit striatal "direct pathway" (DP) MSN that
activate tics and compulsions (Kalanithi et al., 2005; Kataoka
et al., 2010; Burguiere et al., 2013; Xu et al., 2015a). Both TS and
OCD are associated with hyperactivity of regional (somatosen-
sory or orbitofrontal) cortical output neurons, as well as impaired
sensorimotor gating evidenced by PPI (prepulse inhibition) def-
icits (Swedo et al., 1992; Breiter et al., 1996; Ziemann et al., 1997;
Edgley and Lemon, 1999; Gilbert et al., 2004; Mantovani et al.,
2006; Swerdlow and Sutherland, 2006; Ahmari et al., 2012).
Transcranial magnetic stimulation (TMS) conﬁrms that both
disorders involve not cortical inhibition but disinhibition
(Ziemann et al., 1997; Gilbert et al., 2004; Mantovani et al.,
2006). Reﬂecting cortical hyperactivity, elevated corticostriatal
glutamatergic efﬂux was observed in OCD (Rosenberg et al.,2000), and repetitive, optogenetic light-evoked orbitofrontal cor-
ticostriatal glutamatergic excitation of striatal MSN causes OC-
like behavior in mice (Ahmari et al., 2013). Similarly, monkey and
rat stereotaxic drug studies show that disinhibiting sensorimotor
corticostriatal glutamate output is essential to generate tic-like
behaviors, while inhibiting it is essential to diminish them
(Pogorelov et al., 2015). These data indicate that corticostriatal
glutamate can elicit, not just mediate, TS- and OC-like behaviors.
CSTC hyperactivity may originate in some etiologic forms
of TS as impairment of inhibitory interneurons (Verkerk et al.,
2003; Minzer et al., 2004; Penagarikano et al., 2011) or of
inhibitory neurotransmission – including defective histamine
neurotransmission causing loss of histaminergic nigrostriatal
(as well as cortical) presynaptic inhibition in Hdc (histidine
decarboxylase) gene deletion-associated hyperdopaminergic
forms of human TS or mouse TS-like orofacial and snifﬁng
stereotypies (Ercan-Sencicek et al., 2010; Karagiannidis et al.,
2013; Castellan Baldan et al., 2014; Xu et al., 2015b). Similarly,
diminished DAT (dopamine transporter) (Fox et al., 2013) or
MAO-A (monoamine oxidase-A) (Bortolato et al., 2011) trigger
hyperdopaminergic tic-like and/or OC symptoms in mice. But
even these hyperdopaminergic TS etiologies involve striatal
immediate-early gene induction that also depends on coin-
cident glutamate input (Rapanelli et al., 2014; Castellan
Baldan et al., 2014), suggesting that dopamine (DA) and
glutamate co-induce striatal CSTC output to mediate or elicit
tics and compulsions.
TS and OCD subjects also display striatal desensitization and
volumetric damage in response to excess corticostriatal gluta-
mate, excess nigrostriatal DA, and/or defective inhibitory inter-
neurons (Peterson et al., 1993, 1998; Menzies et al., 2008).
Similarly, a striatal motor pathway imbalance in TS and OCD
between motion-suppressing output from DA D2-receptor-
expressing (D2þ) striatal IP MSN and motion-activating output
from DA D1-receptor-expressing (D1þ) striatal DP MSN, favoring
IP inactivity and DP hyperactivity, which was proposed to arise
from primary nigrostriatal hyperdopaminergia or striatal inter-
neuron dysfunction (Mink, 2001; Albin and Mink, 2006; Denys
et al., 2013; Castellan Baldan et al., 2014), was earlier proposed,
and documented in mice, to arise from chronic hyperactive
glutamatergic input to the striatum – where glutamate's excita-
tion of D1þ striatal DP MSN is facilitated by striatonigral DA, but
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gral DA (Campbell et al., 1999b).
Lastly, hyperglutamatergic CSTC tic circuitry explains why
TS drugs work: postsynaptic D2 receptor antagonists (e.g.,
haldol) excite both D2þ cortical inhibitory interneurons and
striatal IP MSN, while clonidine reduces excitatory noradre-
nergic (NE) input to amygdalar and cortical glutamatergic
neurons (Lichter and Jackson, 1996; Campbell et al., 1999b;
Nordstrom and Burton, 2002; Minzer et al., 2004).
1.2. Hyperglutamatergic D1CT-7 "Ticcy" mice
A causative role for chronic cortical and amygdalar glutamatergic
neuron output in TS and OCD was ﬁrst proposed from analysis
of the ﬁrst genetically engineered mouse model of TSþOCD (and
to date the only to exhibit TS-like head and body twitches as well
as comorbid OC-like behaviors) – the D1CT-7 "Ticcy" transgenic
mouse (Campbell et al., 1999a, 1999b; Nordstrom and Burton,
2002). As the ﬁrst transgenic "brain circuit-test," preceding by a
decade optogenetic artiﬁcial channel transgenes that directly
depolarize and ﬁre neurons, Ticcy mice instead express an
artiﬁcial neuropotentiating transgene that enhances neurons'
responsiveness to their own endogenous neurotransmitters.
This was achieved by DA D1 receptor (DRD1) gene promoter-
targeted expression of an artiﬁcial exon encoding the exclusively
intracellular A1 subunit of cholera toxin (CT) (Campbell et al.,
1999a), which physiologically activates any cell type by cova-
lently activating its stimulatory G protein GS, to chronically
stimulate adenylate cyclase activity and intracellular levels of
the second messenger 30,50-cyclic adenosine monophosphate
(cAMP) (Burton et al., 1991; Zeiger et al., 1997). Furthermore,
D1CT expression in the D1CT-7 ("Ticcy") line of such transgenic
mice was regionally restricted to a cortical/limbic subset of brain
D1þ neurons, with no expression in striatum. This cortical/
limbic D1þ neuron potentiation induces in D1CT-7 mice volun-
tarily-suppressible, juvenile-onset tics (Nordstrom and Burton,
2002) and compulsions (Campbell et al., 1999a); glutamatergically
unbalanced striatal DP MSN hyperactivity and IP MSN inactivity
that remains sensitive to D2 antagonist reactivation (Campbell
et al., 1999b); increased tic severity in males (Nordstrom and
Burton, 2002); stress sensitivity (McGrath et al., 1999a, 1999b); and
alleviation by major TS drug classes (Nordstrom and Burton,
2002; Campbell et al., 1999b) – thus showing the greatest
behavioral homology to TSþOCD of animal models reported to
date (Burke and Lombroso, 2004; Pittenger et al., 2011). Based on
the hyperglutamatergic status of the Ticcy mice's cortical circuit
(normal mice show slower-onset and calmer pentylenetetrazole-
kindled cortical seizures, and less-pronounced glutamatergic
drug-induced locomotion, whereas neither normal nor Ticcy
mice show spontaneous seizures) (Campbell et al., 2000;
McGrath et al., 2000) and on the known cortical and limbic
excitatory outputs triggered by their potentiated D1þ neurons
(which comprise a small, intermediate-layer cortical sheet of
somatosensory/insular/piriform D1þ glutamatergic pyramidal
output neurons and a cluster of amygdalar intercalated nucleus
D1þ GABAergic interneurons, that normally in response to DA
respectively trigger glutamatergic excitation of the striatum from
deep-layer somatosensory-motor-orbitofrontal cortical pyrami-
dal and amygdalar pyramidal output neurons) (Campbell et al.,
1999a, 1999b, 1999c, 2000), these D1CT-7 Ticcy mice comprised adirect test of the hypothesis that corticostriatal and/or amygda-
lostriatal glutamatergic circuit hyperactivity can cause tics and
compulsions (Campbell et al., 1999a; Carlsson, 2000; Nordstrom
and Burton, 2002). The D1CT-7model's TS-like behavior and drug
responses – and its newly claimed PPI deﬁcits (Godar et al., 2015)
– demonstrate its "face validity" as model for TS. Moreover, early
objections to its "construct validity" (Swerdlow and Sutherland,
2005, 2006) – namely, that its neuropotentiated "hyperactive"
circuits did not concord with then-claimed "hypoactive" circuits
in TS; and that it was an "artiﬁcial" construct without etiological
relevance – have subsequently diminished with the awareness
that, ﬁrst, premonitory urges and tics in TS show hypoactivity
only within executive-control circuits, but primary hyperactivity
within the same somatosensory, insular and efferent motor
output circuits hyperactivated in the mice (Campbell et al.,
1999a; Bohlhalter et al., 2006; Wang et al., 2011; Church and
Schlaggar, 2014); and, second, that such transgenic brain circuit-
testing approaches, including later optogenetic techniques
(Ahmari et al., 2013; Ahmari and Dougherty, 2015), impart
knowledge about the circuitry and therapy of TS- and OC- like
behaviors irrespective of etiology. Awareness of glutamate's role
in eliciting tics and compulsions in D1CT-7mice (Sah and Sallee,
2002; Burke and Lombroso, 2004; Joel, 2006; Ting and Feng, 2008;
Wang et al., 2009; Pittenger et al., 2011; Wu et al., 2012; Ahmari
and Dougherty, 2015) has helped inspire clinical studies of this
neurotransmitter's role in TS and OCD (Chakrabarty et al., 2005;
Singer et al., 2010); successful trials of antiglutamatergics for OCD
and TTM (Laﬂeur et al., 2006; Grant et al., 2007, 2009); and trials of
a D1 antagonist for TS (Gilbert et al., 2014) and OC-spectrum
gambling disorder (Grant et al., 2014).
Identifying pharmacological targets within the Ticcy
mice's hyperglutamatergic CSTC "tic-circuit" that can serve
as "circuit breakers" may provide new leads in functional
neuroanatomy and pharmacotherapy. Here we conﬁrm four
such postulated "tic-circuit breaker" drugs alleviate or dimin-
ish their tics – a serotonin 5-HT2a,c receptor antagonist
(ritanserin) and a NE alpha-1 receptor antagonist (prazosin)
that block corticostriatal and/or amygdalostriatal glutamate
output (Marek and Aghajanian, 1999), a presynaptic agma-
tine/imidazoline I1 receptor agonist (moxonidine) that blocks
striatal DP MSN output (Tanabe et al., 2006), and a presynap-
tic DA D2 receptor agonist (bromocriptine) that blocks nigros-
triatal DA output (Ceccherini-Nelli and Guazzelli, 1994). This
supports the contention that hyperactivity of cortico/amyg-
dalostriatal and cortico/amygdalonigral glutamate output
elicits tics, and that drugs capable of interrupting this
hyperglutamatergic tic-circuit are prospective pharma-
cotherapies for neurogenic tics in human TS.2. Results
Deep-layer cortical pyramidal glutamatergic output neurons
express excitatory serotonin 5-HT2a,c receptors (Sheldon and
Aghajanian, 1991; Nestler, 1997; Jakab and Goldman-Rakic,
1998; Marek and Aghajanian, 1998, 1999; Aghajanian and
Marek, 1999), suggesting a potential therapeutic role in TS
for pure 5-HT2a,c antagonists like ritanserin, which also has
anxiolytic activities both clinically and in rodents (Ceulemans
et al., 1985; Danjou et al., 1992; Gao and Cutler, 1993)
Fig. 1 – Ritanserin alleviates tics in a transgenic model of Tourette's syndrome. Panel A. Ritanserin (1 mg/kg, i.p.) normalizes
tics in D1CT-7 "Ticcy" transgenic mice. Data are shown as a bar graph of the mean numberþSEM of head or body twitches
occurring over 15 min of videotaped observation. Overall signiﬁcance of genotype effect [F(1,17)¼8.771; P¼0.0087, n¼8 Tg,
11C], drug effect [F(1,17)¼14.113; P¼0.0016, n¼8 Tg, 11C], and genotype x drug interaction [F(1,17)¼8.487; P¼0.0097, n¼8 Tg,
11C] was established by repeated measures ANOVA, followed by individual between-group Mann–Whitney U-test of
genotype effect and within-group Wilcoxon Signed Rank test of drug effect, with signiﬁcance established at tied Po0.05,
which revealed both elevated tics in transgenic mice and reduction of their tics by ritanserin treatment. Panel B. Tic reduction
by ritanserin is not associated with reduced locomotion. Data are shown as a bar graph of the mean numberþSEM of cage
midline crossings, an assay of locomotion, occurring over 15 min of videotaped observation. Non-signiﬁcance of all effects
and interactions was established by repeated measures ANOVA, which revealed that 1 mg/kg i.p. ritanserin did not alter
locomotor activity, indicating that the tic-suppressing effect of ritanserin in Ticcy mice occurs in the absence of general
locomotor inhibition or sedation. Statistics: initial repeated measures ANOVA (n¼8 transgenic, 11 control non-transgenic
mice) was performed to establish overall signiﬁcance on tics or locomotion of genotype effect, drug effect, or genotype x drug
interaction, after which individual comparisons of the non-parametrically distributed tic data (see Methods) or the
parametrically distributed locomotion data were respectively performed by between-group non-parametric Mann–Whitney
U-tests or parametric unpaired 2-tailed Student's t-tests of genotype effects, and within-group non-parametric Wilcoxon
Signed Rank tests or parametric paired 2-tailed Student's t-tests of drug effects, with signiﬁcance of effect on non-
parametrically distributed tic counts assumed at tied Po0.05 and on parametrically-distributed locomotor event counts
assumed at Po0.05. Abbreviations: Tg (D1CT- 7 "Ticcy" transgenic female mice); C (non-transgenic control female mice); Veh
(saline vehicle i.p. injection); Rit (1 mg/kg i.p. ritanserin injection); **Po0.01 for between-group (Tg vs. C, Veh) comparison
(unpaired Mann–Whitney U-test), þPo0.05 for within-group, between-treatment (Tg, Veh vs. Rit) comparison (paired
Wilcoxon Signed Rank test), n¼8 Tg, 11C mice.
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receptors (Gibson et al., 1994) that may similarly reduce
excitatory amygdalar glutamatergic output to limbic and
orbitofrontal cortices, and to nigrostriatal and striatal motor
circuits. The ability of ritanserin to suppress tics at a con-
centration not inhibitory to normal mouse locomotor activity
was tested in Fig. 1. While the Ticcy D1CT-7 transgenic (Tg)
mice show multifold numbers of TS-like twitches compared
to control non-transgenic control (C) mice, their tics are
restored to control levels by acute ritanserin (1 mg/kg, i.p.)
treatment (Fig. 1, Panel A, black bars). Ritanserin treatment
did not signiﬁcantly decrease the control mice's normal,
baseline level of infrequent twitching (Fig. 1, Panel A, white
bars). Nor did ritanserin treatment signiﬁcantly reduce in
either Ticcy or control mice the level of cage midline cross-
ings/15 min, a measure of locomotor activity (Fig. 1, Panel B).
This is consistent with previous reports that this 1 mg/kg i.p.
ritanserin dosage in rodents, while psychoactive in reducinganxiety, does not inhibit spontaneous locomotion (Ninan and
Kulkarni, 1998). Our data indicate that acute ritanserin treat-
ment selectively suppresses abnormal ticcing without inhi-
biting normal, baseline spontaneous locomotor activity.
Another drug thought to decrease corticostriatal glutama-
tergic output is the alpha-1 antagonist, prazosin (Fig. 2),
whose alpha-1 NE receptors were shown to be co-expressed
with the 5-HT2a,c receptor targets of ritanserin on deep-layer
cortical pyramidal glutamatergic output neurons (Marek and
Aghajanian, 1999). Consequently we tested in Fig. 2 the ability
of prazosin to suppress corticostriatal glutamatergic tics, at a
concentration reportedly not inhibitory to mouse locomotor
activity but capable of psychoactively countering DA-
dependent anorexia (Wellman and Davies, 1992; Wellman
et al., 1997; Cheng and Kuo, 2003). Like ritanserin, acute
prazosin treatment (3 mg/kg, i.p.) treatment of the Ticcy
D1CT-7 transgenic (Tg) mice decreased their elevated tic
counts to the level of control (C) littermates (Fig. 2, Panel A,
Fig. 2 – Prazosin alleviates tics in a transgenic model of Tourette's syndrome. Panel A. Prazosin (3 mg/kg, i.p.) normalizes tics in
D1CT-7 "Ticcy" transgenic mice. Data are shown as a bar graph of the mean numberþSEM of head or body twitches occurring
over 15min of videotaped observation. Overall signiﬁcance of genotype effect [F(1,11)¼10.259; P¼0.0084, n¼7 Tg, 6C], drug
effect [F(1,11)¼21.495; P¼0.0007, n¼7 Tg, 6C], and genotype x drug interaction [F(1,11)¼18.424; P¼0.0013, n¼7 Tg, 6C] was
established by repeated measures ANOVA, followed by individual between-group Mann–Whitney U-test of genotype effect and
within-group Wilcoxon Signed Rank test of drug effect, with signiﬁcance established at tied Po0.05, which revealed both
elevated tics in transgenic mice and reduction of their tics by prazosin treatment. Panel B. Tic reduction by prazosin is not
associated with reduced locomotion. Data are shown as a bar graph of the mean numberþSEM of cage midline crossings, an
assay of locomotion, occurring over 15 min of videotaped observation. Non-signiﬁcance of all effects and interactions was
established by repeated measures ANOVA, which revealed that 3 mg/kg i.p. prazosin did not alter locomotor activity, indicating
that the tic-suppressing effect of prazosin in Ticcy mice occurs in the absence of general locomotor inhibition or sedation.
Statistics: Initial repeated measures ANOVA (n¼7 transgenic, 6 control non-transgenic mice) was performed to establish overall
signiﬁcance on tics or locomotion of genotype effect, drug effect, or genotype x drug interaction, after which individual
comparisons of the non-parametrically distributed tic data (see Methods) or the parametrically distributed locomotion data were
respectively performed by between-group non-parametric Mann–Whitney U-tests or parametric unpaired 2-tailed Student's t-
tests of genotype effects, and within-group non-parametric Wilcoxon Signed Rank tests or parametric paired 2-tailed Student's
t-tests of drug effects, with signiﬁcance of effect on non-parametrically distributed tic counts assumed at tied Po0.05 and on
parametrically-distributed locomotor event counts assumed at Po0.05. Abbreviations: Tg (D1CT- 7 "Ticcy" transgenic female
mice); C (non-transgenic control female mice); Veh (saline vehicle i.p. injection); Praz (3 mg/kg prazosin i.p. injection); **Po0.01
for between-group (Tg vs. C, Veh) comparison (unpaired Mann–Whitney U-test), þPo0.05 for within-group, between-treatment
(Tg, Veh vs. Praz) comparison (paired Wilcoxon Signed Rank test), n¼7 Tg, 6C mice.
b r a i n r e s e a r c h 1 6 2 9 ( 2 0 1 5 ) 3 8 – 5 342black bars). Prazosin treatment likewise did not signiﬁcantly
decrease the control mice's normal, baseline level of infre-
quent twitches (Fig. 2, Panel A, white bars), nor signiﬁcantly
alter locomotion (cage midline crossings) in either the Ticcy
transgenic mice or control mice (Fig. 2, Panel B). Our data
indicate that acute treatment with prazosin selectively sup-
presses abnormal ticcing without inhibiting normal, baseline
spontaneous locomotor activities.
The agmatine/imidazoline-1 agonist moxonidine
(Fairbanks and Wilcox, 1999; Zhu et al., 1999; Taksande
et al., 2010; Dixit et al., 2014), a less-sedating, less-
hypotensive and less alpha-2 NE receptor cross-speciﬁc
relative of the TS-drug clonidine, exerts distinct central
nervous system actions due to its imidazoline-1 (I-1) receptor
speciﬁcity: whereas clonidine's presynaptic alpha-2 NE ago-
nist action decreases NE stimulation of anxiogenic amygdalar
glutamatergic output to the limbic cortex and striatum
(Lichter and Jackson, 1996; Nordstrom and Burton, 2002),
moxonidine, as a presynaptic I-1 receptor agonist that bothinhibits striatal DP and IP MSN (striatal direct- and indirect-
pathway GABAergic output neurons) targeted by glutamate
(Tanabe et al., 2006) and reduces glutamate-triggered neuro-
toxicity (Bakuridze et al., 2009), may suppress the more distal,
striatothalamic-output subcircuits of the CSTC tic circuit.
Consequently we tested the ability of acute i.p. moxonidine
to block hyperglutamatergic-mediated tics at a 0.5 mg/kg
dose sufﬁcient not only for peripheral reduction of blood
pressure (Zhu et al., 1999) but also for CNS reduction of drug
withdrawal-induced anxiety and endogenous anxiety-
dependent compulsive (marble-burying) behavior in rodents
(Taksande et al., 2010; Dixit et al., 2014) (Fig. 3). Like acute
ritanserin and prazosin, acute moxonidine treatment of the
Ticcy D1CT-7 transgenic (Tg) mice decreased their elevated tic
counts to the level of control (C) littermates (Fig. 3, Panel A,
black bars) without decreasing the control mice's normal,
baseline level of infrequent twitches (Fig. 3, Panel A, white
bars) or altering locomotion (cage midline crossings) in either
the transgenic or control mice (Fig. 3, Panel B). Our data
Fig. 3 – Moxonidine alleviates tics in a transgenic model of Tourette's syndrome. Panel A. Moxonidine (0.5 mg/kg, i.p.)
normalizes tics in D1CT-7 "Ticcy" transgenic mice. Data are shown as a bar graph of the mean numberþSEM of head or body
twitches occurring over 15 min of videotaped observation. Overall signiﬁcance of genotype effect [F(1,12)¼8.753; P¼0.012, n¼9
Tg, 5C], drug effect [F(1,12)¼39.656; Po0.0001, n¼9 Tg, 5C], and genotype x drug interaction [F(1,12)¼18.344; P¼0.0011, n¼9
Tg, 5C] was established by repeated measures ANOVA, followed by individual between-group Mann–Whitney U-test of
genotype effect and within-group Wilcoxon Signed Rank test of drug effect, with signiﬁcance established at tied Po0.05,
which revealed both elevated tics in transgenic mice and reduction of their tics by moxonidine treatment. Panel B. Tic
reduction by moxonidine is not associated with reduced locomotion. Data are shown as a bar graph of the mean
numberþSEM of cage midline crossings, an assay of locomotion, occurring over 15 min of videotaped observation. Non-
signiﬁcance of all effects and interactions was established by repeated measures ANOVA, which revealed that 0.5 mg/kg i.p.
moxonidine did not alter locomotor activity, indicating that the tic-suppressing effect of moxonidine in Ticcy mice occurs in
the absence of general locomotor inhibition or sedation. Statistics: initial repeated measures ANOVA (n¼9 transgenic,
5 control non-transgenic mice) was performed to establish overall signiﬁcance on tics or locomotion of genotype effect, drug
effect, or genotype x drug interaction, after which individual comparisons of the non-parametrically distributed tic data (see
Methods) or the parametrically distributed locomotion data were respectively performed by between-group non-parametric
Mann–Whitney U-tests or parametric unpaired 2-tailed Student's t-tests of genotype effects, and within-group non-
parametric Wilcoxon Signed Rank tests or parametric paired 2-tailed Student's t-tests of drug effects, with signiﬁcance of
effect on non-parametrically distributed tic counts assumed at tied Po0.05 and on parametrically-distributed locomotor event
counts assumed at Po0.05. Abbreviations: Tg (D1CT- 7 "Ticcy" transgenic female mice); C (non-transgenic control female mice);
Veh (saline vehicle i.p. injection); Mox (0.5 mg/kg moxonidine i.p. injection); **Po0.01 for between-group (Tg vs. C, Veh)
comparison (unpaired Mann–Whitney U-test), þþPo0.01 for within-group, between-treatment (Tg, Veh vs. Mox) comparison
(paired Wilcoxon Signed Rank test), n¼9 Tg, 5C mice.
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dazoline I-1 receptors are known to localize presynaptically
on and inhibit striatal GABAergic output neurons, can sup-
press cortico/amygdalostriatal glutamate-induced abnormal
ticcing without inhibiting normal, baseline spontaneous
locomotor activities.
The ﬁnal candidate "tic circuit breaker" drug we examined
was the D2 receptor agonist, bromocriptine (Fig. 4), which at low
doses is selectively presynaptic in its action on striatonigral
dopaminergic axon terminals (Ceccherini-Nelli and Guazzelli,
1994), thus inhibiting nigral dopaminergic efﬂux onto DA
receptor-expressing striatal neurons (which should counter the
tic-triggering effect of coincident hyperglutamatergic stimulation
of striatal D1þ DP MSN as well as disinhibit glutamatergically
stimulated D2þ IP MSN). However, bromocriptine is also known
to reduce general locomotor activity as a consequence of its
presynaptically inhibiting DA input to the striatum (Jackson et al.,1988), similar to the effect of typical postsynaptic D2 antagonists
(like haloperidol) used for tic and OC-spectrum disorders (Cohen
et al., 1992). Consequently, we examined bromocriptine's ability
to diminish not only tics but total locomotion events, which are
modulated by the same convergent glutamatergic and dopami-
nergic inputs to striatal DP and IP MSN that mediate tics and
compulsions. At 2 hours post-injection, when in rodents bromo-
criptine is reported to exert its highest presynaptic D2 agonist
effect to inhibit nigrostriatal axonal DA release (Jackson et al.,
1988), the elevated tics in the Ticcy D1CT-7 transgenic (Tg) mice
were decreased to the level of untreated control (C) littermates
(Fig. 4, Panel A, black bars). But unlike acute ritanserin, prazosin,
or moxonidine, acute bromocriptine treatment also signiﬁcantly
decreased control mice's normal, baseline level of infrequent
twitches (Fig. 4, Panel A, white bars) as well as their horizontal
total locomotion events (Fig. 4, Panel B, white bars), indicating
that bromocriptine may be exerting some of its tic-suppressing
Fig. 4 – Bromocriptine suppresses tics in a transgenic model of Tourette's syndrome. Panel A. Bromocriptine (5 mg/kg, i.p.)
suppresses tics in D1CT-7 "Ticcy" transgenic mice. Data are shown as a bar graph of the mean numberþSEM of head or body
twitches occurring over 15 min of videotaped observation beginning 15 min before (Bromo) vs. two hours after (þBromo)
drug injection. Repeated measures ANOVA showed both a signiﬁcant overall effect on ticcing incidence of bromocriptine
treatment [F(1,14)¼42.215; Po0.0001, n¼8 Tg, 8C], and a signiﬁcant genotype x bromocriptine interaction [F(1,14)¼5.385;
P¼0.0359, n¼8 Tg, 8C], justifying individual comparisons of the non-parametrically distributed tic count data by between-
group Mann–Whitney U-test of genotype effect and within-group Wilcoxon Signed Rank test of drug effect with signiﬁcance
established at tied Po0.05, which revealed elevated tics in transgenic mice and reduction of their tics by bromocriptine
treatment, as well as reduction of control mice's baseline twitch count by bromocriptine treatment. Panel B. Bromocriptine is
associated with reduced locomotion in control mice. Data are shown as a bar graph of the mean numberþSEM of locomotion
events occurring over 15 min of videotaped observation beginning 15 min before (Bromo) vs. two hours after (þBromo) drug
injection. Repeated measures ANOVA showed a signiﬁcant overall effect on locomotion events of drug treatment [F(1,14)¼
12.427; P¼0.0034; n¼8 Tg, 8C], justifying individual comparison of bromocriptine's effects on the parametrically distributed
locomotion event count data by within-group, paired 2-tailed Student's t-test, which revealed that 5 mg/kg i.p. bromocriptine
suppressed locomotion events in control mice, indicating that the tic-suppressing effect of bromocriptine in Ticcy and control
mice occurs in conjunction with a general locomotor inhibiting (cataleptic) or sedating effect evident in control mice. Statistics:
initial repeated measures ANOVA (n¼8 transgenic, 8 control non-transgenic mice) was performed to establish overall
signiﬁcance on tics or locomotion of genotype effect, drug effect, or genotype x drug interaction, after which individual
comparisons of the non-parametrically distributed tic data (see Methods) or the parametrically distributed locomotion data
were respectively performed by between-group non-parametric Mann–Whitney U-tests or parametric unpaired 2-tailed
Student's t-tests of genotype effects, and within-group non-parametric Wilcoxon Signed Rank tests or parametric paired
2-tailed Student's t-tests of drug effects, with signiﬁcance of effect on non-parametrically distributed tic counts assumed at
tied Po0.05 and on parametrically-distributed locomotion event counts assumed at Po0.05. Abbreviations: Tg (D1CT- 7 "Ticcy"
transgenic female mice); C (non-transgenic control female mice); Bromo (15 mins pre-injection); þBromo (5 mg/kg i.p.
bromocriptine, 2 h post-injection); *Po0.05 for between-group (Tg vs. C, -Bromo) comparison of genotype effect on non-
parametrically distributed tic counts (unpaired Mann–Whitney U-test), þPo0.05 for within-group, between-treatment
(Bromo vs. þBromo) comparisons of drug effect on non-parametrically distributed Tg and C tic counts (paired Wilcoxon
Signed Rank tests), þþPo0.01 for within-group, between-treatment (C, Bromo vs. þBromo) comparison of drug effect on
parametrically-distributed locomotion event counts (paired 2-tailed Students' t-test), n¼8 Tg, 8C mice.
b r a i n r e s e a r c h 1 6 2 9 ( 2 0 1 5 ) 3 8 – 5 344effects by broadly inhibiting baseline locomotor initiation
mediated by the striatal subcircuit targeted by both convergent
cortical/amygdalar glutamate input and nigral DA input. Such an
effect is consistent with the role of presynaptic striatal DA D2
receptors to reduce various DA-dependent motor activities and
increase catalepsy in mice (Jackson et al., 1988). It is also
consistent with DA's known role as a modulatory inducer of
locomotion both normally and in clinical DA-replacement ther-
apy for parkinsonism; and with parkinsonian side-effects being a
clinical side-effect of presynaptic D2 agonist therapeutic drugs(including pergolide and aripiprazole). A slight reduction of total
locomotion events was also seen in Ticcy mice upon bromocrip-
tine treatment, but did not reach a signiﬁcant level (Fig. 4, Panel B,
black bars). Bromocriptine's suppression of both twitches and, to
a lesser extent, locomotion, in both normal and Ticcy mice
suggests it is acting through a broad, motor-circuit inhibiting
"hypodopaminergic" effect. The incidence of horizontal total
locomotion events in all untreated or bromocriptine treated mice
(Fig. 4, Panel B) was roughly twice their incidence of cage midline
crossings (not shown), consistent with prior reports that
MOVE-URGE 
D2 D1 
CTX/AMY 
SNc 
GLU 
DA 
5-HT2a,c  
alpha-1  
I-1  I-1  
D2 STR 
DP 
STR 
IP 
MOVE-URGE 
SNc 
GLU 
D2 D1 
DA 
CTX/AMY 5-HT2a,c  
alpha-1  
I-1  I-1  
D2 STR 
DP 
STR 
IP 
MOVE-URGE 
D2 D1 
CTX/AMY 
SNc 
GLU 
DA 
5-HT2a,c  RIT  
alpha-1  
I-1  I-1  
D2 STR 
DP 
STR 
IP 
MOVE-URGE 
D2 D1 
CTX/AMY 
SNc 
GLU 
DA 
5-HT2a,c  
PRAZ  alpha-1  
I-1  I-1  
D2 STR 
DP 
STR 
IP 
SNc 
GLU 
D2 D1 
DA 
CTX/AMY 5-HT2a,c  
alpha-1  
I-1  I-1  
MOX  
MOVE-URGE 
D2 
MOX  
STR 
DP 
STR 
IP 
SNc 
GLU 
D2 D1 
DA 
CTX/AMY 5-HT2a,c  
alpha-1  
I-1  I-1  
D2 
BROMO  
STR 
DP 
STR 
IP 
MOVE-URGE 
Fig. 5 – Predicted hyperglutamatergic tic circuit and circuit-breaker drugs' actions. Panel A. Normal circuit controlling motion
and urges. Panel B. Abnormal cortical/amygdalar hyperglutamatergic circuit triggers tics. Panel C. Ritanserin breaks tic circuit
as a cortical/amygdalar 5-HT2a,c antagonist. Panel D. Prazosin breaks tic circuit as a cortical/amygdalar alpha-1 NE antagonist.
Panel E. Moxonidine breaks tic circuit as a striatothalamic I-1 presynaptic agonist. Panel F. Bromocriptine counters tic circuit
as a nigrostriatal DA D2 presynaptic agonist. Symbols: triangles, excitatory glutamatergic pyramidal cortical/amygdalar
output neurons; Filled triangles, hyperactivated glutamatergic output neurons (due to D1CT-7 transgene-potentiated
excitatory afferents in Ticcy mice or genetic/epigenetic alterations in neurogenic TS); circles, target striatal GABAergic
Medium-Spiny (output) Neurons (MSN); Squares, modulatory substantia nigra dopaminergic neurons; rectangular "MOVE-
URGE boxes," behaviors excited or inhibited by striatal MSN output; -, move-urge-exciting or striatal neuron-exciting
neurotransmission; —|, move-urge-inhibiting or striatal-neuron inhibiting neurotransmission; Thicker arrows, increased
neurotransmission; Thicker "MOVE-URGE box," move-urge excitation (e.g., tics, obsessions, compulsions, impulses, cravings,
or hallucinations, depending on topographic parallelism of the circuit). Abbreviations: GLU, glutamate (excitatory); DA,
dopamine (modulatory); CTX, cortex; AMY, amygdala; STR, striatum; SNc, substantia nigra pars compacta; D1, dopamine D1
excitatory postsynaptic receptors; D2, dopamine D2 inhibitory postsynaptic (left) or presynaptic (middle) receptors; DP, striatal
direct pathway (D1-receptor excited, motor/urge-activating striatothalamic) MSN; IP, striatal indirect pathway (D2-receptor
inhibited, motion/urge-suppressing striatopallidal) MSN; 5-HT2a,c, serotonin 5-HT2a,c excitatory postsynaptic receptors;
alpha-1, norepinephrine alpha-1 adrenergic excitatory postsynaptic receptors; I-1, imidazoline-1 (agmatine) inhibitory
presynaptic receptors; RIT, ritanserin; PRAZ, prazosin; MOX, moxonidine; BROMO, bromocriptine.
b r a i n r e s e a r c h 1 6 2 9 ( 2 0 1 5 ) 3 8 – 5 3 45locomotor initiations in both control and Ticcy mice represent
initiations of extended locomotor sequences (Campbell et al.,
1999a; Nordstrom and Burton, 2002). Lastly, the bromocriptine
study's Ticcy group exhibits a lower population mean tic count
and standard error than in the other drug studies, due to the
group's smaller proportion of Ticcy mice with more severe tics.
Because Ticcy mice's symptom severity varies epigenetically
between individuals, which is controlled for by using a
repeated-measures drug design (see Section 5.6), Ticcy groups'
mean tic count and standard error differ between drug studies
based on each study's proportion of Ticcy mice with more severe
or less severe tics.3. Discussion
3.1. A proposed hyperglutamatergic "tic circuit"
The D1CT-7 "Ticcy" mouse model of TSþOCD was the ﬁrst
brain "circuit test" of a complex psychomotor disease, created
by transgenic neuropotentiation of a molecularly and region-
ally restricted CSTC circuit element (Campbell et al., 1999a,
1999b; Nordstrom and Burton, 2002). The CSTC subcircuit
chronically potentiated in Ticcy mice is a small population of
dopaminoceptive D1þ somatosensory cortical and limbic
neurons thought to be hyperactive in human TS and OCD,
and known to trigger deep-layer cortical and amygdalar
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and striatopallidal IP MSN subcircuits and of efferent nigros-
triatal dopaminergic neuron subcircuits. The D1CT-7 Ticcy
model thus represents a test of the effect of chronic, coin-
cident input of excitatory forebrain glutamate and modula-
tory nigral DA upon striatal output – a "hyperglutamatergic
tic-circuit" model (Fig. 5). This model allows us to compare
transient, minimal, and usually non-coincident glutamate
and DA striatal inputs associated with normal motor beha-
vior (Fig. 5, Panel A) to chronic, potentiated, and coincident
glutamate and DA striatal inputs associated with abnormal
TSþOCD-like motor behaviors (Fig. 5, Panel B); and allows us
to both model (Fig. 5, Panels C–F) and therapeutically vet new
proposed classes of "tic-circuit breaker" drugs.
What is the role of normal transient, minimal, and non-
coincident glutamate and DA action on CSTC circuitry and
behavior? Without coincident action (Fig. 5, Panel A), striatal
DP MSN (movement- and urge- stimulating, direct-pathway
GABAergic output neurons that co-express excitatory gluta-
mate receptors and co-excitatory DA D1 receptors) should
respond either to cortical/amygdalar glutamate or to nigral
DA by eliciting movements and urges. Meanwhile, striatal IP
MSN (movement- and urge- suppressing, indirect-pathway
GABAergic output neurons that co-express excitatory gluta-
mate receptors and counter-inhibitory DA D2 receptors)
should respond to cortical/amygdalar glutamate by suppres-
sing movements and urges, but to nigral DA by eliciting them.
Tonic, baseline levels of DA in the striatum are thus likely
needed to block excitation of movement-suppressing IP MSN
and permit excitation of movement-exciting DP MSN by
cortical/amygdalar fast-acting glutamatergic triggers of
voluntary movements and urges. Cortical GABAergic inter-
neurons' inhibitory "executive control" will in turn limit the
expression of such glutamatergic triggers of voluntary move-
ments and urges unless cortical DA rises to the level of
inhibiting these D2þ cortical GABAergic interneurons and
potentiating the D1þ cortical glutamatergic output neurons.
In this regard, the seeming paradox of glutamatergic psycho-
motor induction by NMDA glutamate receptor antagonists
like PCP is thought to be due to these drugs primarily
inhibiting either striatal D2þ IP MSN that suppress motion
and urges, or cortical D2þ GABAergic interneurons that
suppress corticostriatal glutamate output to striatal NMDA
and non-NMDA (e.g., AMPA) glutamate receptors (McGrath
et al., 2000; Homayoun and Moghaddam, 2007).
What then, is the role of abnormal chronic, potentiated,
and coincident glutamate and DA action on CSTC circuitry
and behavior? This circuit state could originate in TS etiolo-
gically either from excessive DA (exciting striatal MSN and
D1þ cortical-limbic neuron glutamate output), excessive
glutamate (exciting striatal MSN and nigrostriatal DA output),
or insufﬁcient GABA (disinhibiting D1þ cortical-limbic neuron
glutamate output and striatal MSN). But regardless of etiol-
ogy, we propose that when such chronic cortical/limbic
glutamatergic neuron hyperactivity does occur, the conver-
gence of its hyperglutamatergic input to striatal circuits and
of its parallel hyperglutamatergic-inducible nigral DA input to
those same striatal circuits will elicit chronic tics and urges,
by chronically unbalancing those striatal circuits in favor of
tic induction via striatal DP MSN (Fig. 5, Panel B). This "ticcircuit" model is based on a prior "cortical/limbic glutama-
tergic neuron (CGN) hyperactivity" model of tics and compul-
sions (Campbell et al., 1999a, 1999b; Carlsson, 2000; Rosenberg
et al., 2000; Nordstrom and Burton, 2002), reﬁned to add
corticonigral glutamate excitation of nigrostriatal DA input
(Singer et al., 2010; Denys et al., 2013).
The mechanism by which chronic glutamate is proposed
to unbalance striatal circuit output, causing tics and urges,
relies on triggering such coincident glutamate and DA striatal
input (Fig. 5, Panel A vs. B): ﬁrst, cortical/amygdalar glutamate
excites both the movement/urge-activating GABAergic stria-
tal direct-pathway (STR DP) MSN and the nigral DA neurons
that co-excite these same STR DP MSN (which co-express
excitatory DA D1 receptors). Second, the otherwise counter-
balancing cortical/amygdalar glutamate excitation of move-
ment/urge-suppressing GABAergic striatal indirect-pathway
(STR IP) MSN (which co-express inhibitory DA D2 receptors) is
inhibited by the glutamatergically-excited nigrostriatal
DA input.
Alternatively, chronic glutamate-initiated DA inhibition of
STR IP MSN could also occur by a pharmacodynamic mechan-
ism that would not require glutamatergic excitation of
nigrostriatal DA input (Campbell et al., 1999b): Chronic fore-
brain glutamatergic hyperexcitation of the STR IP MSN could
instead trigger their inhibitory D2 receptors to pharmacody-
namically cross-supersensitize to even normal, tonic levels of
nigral DA input (Wolf et al., 1996), which would allow even
tonic DA to counter STR IP MSNs' over-excitation by gluta-
mate. But either chronic glutamate-initiated mechanism
would still unbalance the tic/urge-triggering STR DP and tic/
urge-suppressing STR IP subcircuits in favor of chronic STR
DP hyperactivity causing chronic tics and urges.
Given this "hyperglutamatergic tic circuit" where gluta-
mate and DA synergize at the striatal direct pathway to elicit
tics, but antagonize each other at the striatal indirect path-
way to fail to suppress tics, the mechanisms by which the
four tested "circuit-breaker" drugs would then act on this tic
circuit to alleviate or suppress tics are diagrammed (Fig. 5,
Panel B vs. Panels C–F):
First, ritanserin (Fig. 5, Panel C) and prazosin (Fig. 5, Panel
D) antagonize different – but co-expressed – excitatory recep-
tors (respectively, serotonin 5-HT2a,c and alpha-1 NE recep-
tors) located on the deep-layer cortical pyramidal output
neurons that glutamatergically excite the striatum and sub-
stantia nigra. Prazosin may also inhibit amygdalar glutamate
output to striatal and nigral targets, as well as to the limbic
cortex. Their blocking cortico/amygdalostriatal and cortico/
amygdalonigral hyperglutamatergic output would thus "cir-
cuit-break" these neurons' chronic glutamatergic excitation
of their target striatal and nigral neurons, alleviating tics.
Moxonidine (Fig. 5, Panel E) acts more distally on this CSTC
circuit loop, upon imidazoline I-1 autoreceptors on the target
striatal GABAergic DP MSN and IP MSN themselves, presy-
naptically inhibiting the striatothalamic output of the
glutamatergically-hyperactivated STR DP MSN that would
otherwise elicit tics. Bromocriptine (Fig. 5, Panel F), under
experimental conditions where it selectively acts as a pre-
synaptic D2 autoreceptor agonist on nigrostriatal DA neu-
rons, causes "hypodopaminergia" – thus inhibiting the D1þ
STR DP MSN that stimulate tics and disinhibiting the D2þ STR
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dopaminergically inhibits glial glutamate release from GLT1
reverse transport (Shirasaki et al., 2010), hence might also
suppress tics by reducing cortical or striatal perisynaptic
glutamate concentrations. However, bromocriptine's unique
suppression of normal mouse locomotion in our study is
more consistent with a hypodopaminergic (parkinsonian)
mechanism of action. Overall, the effectiveness of these four
classes of drugs in either selectively alleviating tics (i.e.,
ritanserin, prazosin, moxonidine) or less selectively suppres-
sing both tics and locomotion (i.e., bromocriptine) undergirds
the potential validity of this forebrain hyperglutamatergic
circuit model of neurogenic tics and urges.
3.2. Clinical implications
What is the therapeutic potential of these four "tic circuit-
breakers" in treating human TS and its comorbid OC symp-
toms? Our experiments predict that these four drugs might
acutely alleviate tics in TS and in TSþOCD. But one limitation
of our study is that it cannot similarly predict their efﬁcacy
against OC symptoms in TSþOCD or in OC disorders, because
we cannot directly assay acute, short-term drug effects on the
Ticcy mice's complex repertoire of compulsions, which must
be monitored across long-term time-sampling or observation
windows. Nor can we chronically administer these drugs to
the Ticcy mice, due to the interpretive confound of the Ticcy
mice's extreme anxiety in response to anxiogenic stressors
(Campbell et al., 1999a; McGrath et al., 1999a, 1999b), which
includes repeated drug injections or surgical implantation. A
second limitation of our study is that it is based only on the
analysis of tics in female Ticcy mice rather than in both
genders: due to their anxiogenic behavior and TTM/DTM-like
commensal (as well as self-directed) over-grooming compul-
sions, females of the D1CT-7 transgenic strain mate and raise
pups poorly, necessitating our use of Ticcy males to breed
with control females to maintain the colony, while Ticcy
females are retained for drug studies (see Section 5.1). Hence
our conclusions can only be formally drawn for tics as
manifested in Ticcy females – although, as in human TS
(Robertson, 2000), their ticcing is only less severe than Ticcy
males' but otherwise indistinguishable (Nordstrom and
Burton, 2002). Apart from these experimental limitations,
the parallelism and overlap of CSTC circuits mediating the
premonitory urges preceding tics and compulsions – which
likely underlies their frequent co-presentation (Frankel et al.,
1986) – does permit some predictions of these drugs' potential
efﬁcacy for both disorders, based on our and others'
experimental data:
First, ritanserin's acute alleviation of Ticcy mice's tics
suggests human tics may similarly respond not just to
"mixed" 5-HT2/D2 antagonists, like the atypical neuroleptics
risperidone (Bruun and Budman, 1996) and ziprasidone
(Sallee et al., 2000) shown to be effective in TS pilot studies,
but also to "pure" 5-HT2 antagonists like ritanserin. So far
ritanserin has been used in humans to treat anxiety
(Ceulemans et al., 1985; Barone et al., 1986; Danjou et al.,
1992), based on its 5-HT2c-antagonist-mediated suppression
of amygdalar and "limbic cortex" glutamatergic output
(Gibson et al., 1994). Yet ketanserin – a ritanserin-related,non-anxiolytic, hypotensive antagonist of both 5-HT2a and,
weakly, alpha-1 NE receptors (Hosie, et al., 1987; Brogden and
Sorkin, 1990) – was partially effective in a small clinical trial
of childhood-onset TS (Bonnier, et al., 1999). We predict
ketanserin would block cortical-limbic glutamate output
more weakly than ritanserin, a drug that could inhibit not
just cortical glutamatergic neurons' 5-HT2a,c receptors and
their output tics and urges (Sheldon and Aghajanian, 1991;
Marek and Aghajanian, 1998, 1999) but also inhibit amygdalar
glutamatergic neurons' 5-HT2c receptors and their output of
tic-aggravating anxiety (Goetz, 1992; Gibson et al., 1994).
Bolstering that prediction, ritanserin counters serotonergic
drug-induced tic-like and OC/craving-like symptoms (Willins
and Meltzer, 1997; Ciccocioppo et al., 1999).
Second, clinical studies of the other drugs bolster our data
on their potential efﬁcacy for TS and OC disorders: prazosin
clinically is prescribed only as an antihypertensive drug, but
alleviates alcohol craving (Simpson et al., 2009), which is
thought to involve CSTC circuits shared with OC-spectrum
impulse control disorder (Grant et al., 2014). Moxonidine
likewise is clinically prescribed only as a centrally acting
antihypertensive, but reduces rigidity in a hypodopaminergic
mouse model of parkinsonism, supposedly by inhibiting STR
IP MSN output (Tanabe et al., 2008) – which implies it should
also reduce hyperdopaminergic or hyperglutamatergic tics by
similarly inhibiting STR DP MSN output. Furthermore, in mice
moxonidine is not only antihypertensive but also inhibits
anxiety and anxiety-dependent OC behaviors (Taksande
et al., 2010; Dixit et al., 2014). Low-dose bromocriptine reduces
human OC symptoms (Ceccherini-Nelli and Guazzelli, 1994),
hence should be tested for at least TSþOCD. Furthermore, its
speciﬁcity as a presynaptic D2 agonist may permit it to
alleviate TS with more efﬁcacy than that reported for mixed
D1/D2 agonists with postsynaptic D1 agonist activity, like
pergolide (Gilbert et al., 2000).
Finally, we propose it would be fruitful to clinically
examine the therapeutic potential of these and future pro-
posed "hyperglutamatergic CSTC circuit" breaking drugs
upon not only TS, TSþOCD, and OC/impulse-control disor-
ders; but also upon all psychotic-spectrum disorders and
psychomotor side effects of therapeutic drugs or drugs of
abuse – all of which we suspect similarly necessitate hyper-
active glutamate output from topographically-parallel fore-
brain CSTC circuit loops.4. Conclusion
Tics and comorbid compulsions may be mediated, and in
some etiologies triggered, by chronic and coincident efﬂux of
somatosensory cortical/amygdalar glutamate and nigral DA
onto target striatal direct and indirect pathway circuits. In
such "hyperglutamatergic CSTC circuit" models – a circuit
effect mimicked by D1CT-7 "Ticcy" transgenic mice – pre-
monitory urges, tics, compulsions, impulses, cravings, obses-
sions, hallucinations, and their shared endophenotypes such
as PPI/sensorimotor gating deﬁcits, may be triggered
by primary or secondary chronic forebrain glutamatergic
hyperexcitation of the striatum and substantia nigra, with
the latter hyperglutamatergic nigral effect permitting
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rons' motion/urge-activating (direct) vs. motion/urge-sup-
pressing (indirect) outputs, chronically favoring striatal
direct pathway activation of motions and urges. Such symp-
toms would be counteracted not only by drugs that directly
block forebrain glutamatergic neurons' output, but by antago-
nists of these neurons' co-expressed excitatory forebrain
serotonin (ritanserin) and norepinephrine (prazosin) recep-
tors; and by presynaptic agmatinergic or dopaminergic drugs
that respectively would block the downstream glutamate-
triggered target striatothalamic neurons' GABA output (mox-
onidine), or the downstream glutamate-triggered target
nigrostriatal neurons' co-modulatory DA output (bromocrip-
tine). Our observation that Ticcy mice's tics are alleviated by
acute treatment with each of these four drug classes conﬁrms
the drugs may be "circuit-breaking" the mice's hypergluta-
matergic CSTC tic-circuit. Our model merges prior glutamate,
dopamine, serotonin, norepinephrine, and agmatine/imida-
zoline circuit models of tic and OC spectrum- disorders, and
of related psychotic-spectrum disorders and psychotropic
drug effects. Our ﬁndings suggest that the neuropotentiated
D1CT-7 Ticcy transgenic mouse and its hyperglutamatergic
CSTC circuit model will be valid for studying circuit altera-
tions that mediate or underlie psychomotor diseases, and for
designing and testing future clinical interventions, including
new prospective drugs and cortical-limbic or striatal targeted
therapies.5. Experimental procedures
5.1. Animal subjects
30 adult Balb/c-inbred female wild-type control (C) mice and
32 adult Balb/c-inbred female hemizygous D1CT-7 ("Ticcy")
transgenic (Tg) sibling mice were randomly assorted into four
studies of drug effects on tic incidence and locomotion, using
7–9 Tg mice and 5-11C mice per study. The D1CT-7 mouse
strain is available through JAX labs, Bar Harbor, ME, USA, as
cryopreserved stock no. 008367, "C.Cg-Tg(DRD1-ctxA)7Burt/J
mice" strain. Because Tg females breed and nurse poorly due
to Tg-induced anxiogenic ﬂeeing from males and over-
grooming and biting of pups (Campbell et al., 1999a;
Nordstrom and Burton, 2002), Tg males must be used as
breeders to maintain the Ticcy mouse colony, while Tg
females are used for drug studies. All animals were naive to
behavioral or drug assays prior to testing, and experiments
were carried out with the investigators blinded as to the
animals' transgenic or control genotype status and drug
injection status. All mice were housed in groups of 2–5 in a
temperature-controlled room on a 12-h day–night cycle,
allowed unrestricted access to food and water with the
exception of testing times, and drug-treated and videotaped
at the same daytime range of hours to control for the
possibility of circadian ﬂuctuation in drug response. Care
was taken to ensure that breeding and study animals
received no unnecessary discomfort. All animals were main-
tained and procedures were performed in accordance with
the Animal Welfare Act and the NIH Guide for the Care and Use
of Laboratory Animals, under the approval of the University ofMinnesota Institutional Animal Care and Use Committee.
The University of Minnesota Research Animal Resources
facility is fully accredited by the American Association for
the Accreditation of Laboratory Animal Care.5.2. Drugs and injections
Except where indicated, for each drug study mice in both
genotype groups were administered stock solutions of drug or
saline vehicle, 24 h apart, at the injection volumes and at the
acute doses, as well as assayed behaviorally at post-injection
times, that were previously reported to induce a maximal
behavioral effect; and the behavioral observation of video-
tapes were performed blinded as to the animals' transgenic
or control genotype status and drug or saline injection status,
while observation counts were conﬁrmed by a repeat
observer.
Ritanserin (Research Biochemicals International, Natick,
MA, USA) was prepared as a stock solution (0.1 mg/ml
ritanserin, 0.04% Tween-80 in saline) by suspending 10 mg
drug in 2 ml of 2% Tween-80 followed by 50-fold dilution in
saline vehicle (0.9% NaCl). All administrations of ritanserin or
vehicle were delivered intraperitoneally (i.p.) in an injection
volume of 10 ml/kg body weight. The 1 mg/kg i.p. ritanserin
dosage was chosen for this study based on its reported
efﬁcacy in alleviating abnormal behaviors triggered via ser-
otonin 5-HT2a receptors without any concomitant inhibition
of spontaneous locomotor activity (Ninan and Kulkarni,
1998), which we conﬁrmed as described (see Results). Like-
wise, Tween-80/saline vehicles ranging in Tween-80 concen-
trations of up to 32% reportedly have no motor-inhibiting
effects (Castro et al., 1995), which we conﬁrmed by compar-
ison of both tics and locomotor activity levels in saline-
injected vs. 0.04% Tween-80/saline-injected transgenic mice
(not shown).
Prazosin hydrochloride was obtained from Research Bio-
chemicals International (Natick, MA) and dissolved in 0.9%
saline. The drug was administered in a volume of 10 ml/kg
body weight, at a previously reported effective dosage of
3 mg/kg i.p. (Wellman and Davies, 1992; Wellman et al., 1997;
Cheng and Kuo, 2003), and was conﬁrmed to have no
locomotor suppressing effect (see Section 2).
Moxonidine hydrochloride was obtained from Research
Biochemicals International (Natick, MA) and dissolved in 0.9%
saline. The drug was administered i.p. in a volume of 10 ml/
kg body weight, at a previously reported effective dosage of
0.5 mg/kg (Zhu et al., 1999), and was conﬁrmed to have no
locomotor suppressing effect (see Section 2).
Bromocriptine methanesulfonate was obtained from
Research Biochemicals International (Natick, MA) and dis-
solved in 0.9% saline. The drug was administered in a volume
of 10 ml/kg body weight, at a previously reported effective
(but also locomotor suppressing) dosage of 5 mg/kg i.p. that at
2 h post-injection was reported to act selectively on striato-
nigral presynaptic D2 autoreceptors (Jackson et al., 1988), and
was conﬁrmed to confer both tic-inhibitory and mild loco-
motor suppressing effects (see Section 2).
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The incidence of tic-like behavior was determined in video-
tapes of transgenic vs. control non-transgenic littermate
female mice. Tics were deﬁned as any very brief (0.05–0.1 s,
as determined by a duration of 1.5 to 3 frames in 30 fps
videotape recordings) isolated head and/or body jerk or
shake, other than those associated with acoustic startle or
obvious shedding of litter visible on the coat. By this deﬁni-
tion normal mice exhibit tic-like twitches only infrequently,
compared to 3- to 5-fold more frequent tic-like twitches in
D1CT-7 transgenic mice (Nordstrom and Burton, 2002). The
effect on tic incidence of vehicle vs. drug treatment was
determined as the mean number of tics/15 min time unit
(tics/15 min) in transgenic or control mice observed over a
15 min period beginning 30 min after either vehicle or drug
injection and 15 min after introduction of the mice into a new
cage (i.e., after a 15 min cage habituation period), with these
exceptions: 1) In the ritanserin study, 15 min cage habituation
was omitted to avoid confounding a reported anxiolytic effect
of ritanserin (Gao and Cutler, 1993) with any potential
anxiolytic effect of cage habituation, while tic counts (and
midline crossings, as described below in Section 5.4) were
instead observed and analyzed over the entire 30 min period
beginning 30 min after either vehicle or drug injection – but
because subsequent analysis conﬁrmed there was no signiﬁ-
cant effect of 15 min cage habituation upon control or
transgenic tic incidence or midline crossings in the presence
or absence of ritanserin treatment (not shown), the tic and
midline crossing data are displayed in the standard 15-min
time unit; 2) In the bromocriptine study, the post-injection
observations commenced not 30 min but two hours after
injection of bromocriptine, to match the prior reported time
of maximal presynaptic agonist action of the drug in mice
(Jackson et al., 1988), while pre-injection observational data
was obtained 15 min prior to bromocriptine injection with no
saline vehicle injection, likewise to match the prior reported
drug design. Videotapes and/or drug and vehicle samples
were coded to blind observers to the mice's genotype and
drug-injection status, and data were independently logged by
at least two independent observers (raters), with excellent
interrater reliability conﬁrmed by an Intraclass Correlation
Coefﬁcient (ICC)40.8.
5.4. Locomotion behavior quantiﬁcation
To measure spontaneous locomotor activity levels during the
observation periods the same videotapes as described above
were analyzed for the number of cage-midline crossings (the
observed number of locomotion-dependent cage midline
incursions, which reproduces an automated beam-break
design, as described by Nordstrom and Burton (2002). Data
were displayed as the number of midline crossings/15 min. At
least two observers blinded to subject genotype and treat-
ment independently logged the numbers of midline crossings
from the original videotapes, and conﬁrmed excellent inter-
rater reliability of ICC40.8. Additionally, for the bromocrip-
tine study, because this dopaminergic motor output-
inhibiting drug (unlike ritanserin, prazosin and moxonidine)
is reported to also diminish mouse locomotion (Jackson et al.,1988), a more comprehensive behavioral analysis of this
drug's locomotion suppressing effects was also performed,
as described below (Section 5.5).
5.5. Behavioral waveform display analysis of
bromocriptine treated mice
Behavioral waveform display analysis was performed as
previously described (Campbell et al., 1998). Brieﬂy, the
above-described videotapes of drug-naive D1CT-7 transgenic
or control female littermates were continuously observed for
15 min prior to bromocriptine injection and 2 h post-injec-
tion, in each case after 15 min of habituation to a new cage.
EthoMac (v1.10, © The University of Minnesota) software was
used for behavioral state entry, and for calculation and
tabulation of behavioral state event timing, number, and
duration. (EthoMac-analogous commercial software is avail-
able for Windows platforms as "Observer XT," Noldus Infor-
mation Technologies, The Netherlands.) Scored behaviors
included: 1) climbing-leaping (animal standing on its hind
paws in the corner of the cage moving at least three limbs); 2)
still (remaining in one position with an occasional head
movement); 3) rear; 4) gnaw (gnawing against the side of
the Plexiglas cage); 5) locomotion (each such event yielding a
smaller number of cage midline crossings, as described above
in Section 5.4); 6) dig (into the sawdust bedding); 7) groom; 8)
hang (from the wire bar cage lid); 9) eat (bedding picked from
the cage bottom and put into the mouth); 10) sniff; 11) other
(any activity that does not ﬁt into the previous categories).
The total observer-scored number of locomotion events for
each mouse under each post-bromocriptine observation per-
iod, as tabulated by the EthoMac logs, was conﬁrmed by at
least one independent, genotype- and treatment- blinded
observer from original coded videotapes, conﬁrmed to have
ICC40.8 interrater reliability, then statistically compared for
the extent of bromocriptine and genotype effects and dis-
played as the mean number of locomotion events/15 min.
5.6. Statistical analyses
Overall statistical signiﬁcance of a ritanserin, prazosin, mox-
onidine, or bromocriptine drug (within-groups) effect, Ticcy
transgenic (Tg) vs. control (C) wild-type genotype (between-
groups) effect, or a drug by genotype interaction, was deter-
mined in Statview 4.5 (Abacus Corp., Berkeley CA, USA) by
initial repeated-measures analysis of variance (repeated-
measures ANOVA) on both tic and locomotion behavioral
measures, followed by individual between-group unpaired,
two-tailed Student's t-test comparisons of genotype effect
and within-group paired, two-tailed Student's t-test compar-
isons of drug effect, with signiﬁcance assumed at Po0.05, for
parametrically-distributed locomotion data; or individual
between-group Mann–Whitney U-tests of genotype effect
and within-group Wilcoxon Signed Rank tests of drug effect,
with signiﬁcance assumed at tied Po0.05, for the non-
parametrically-distributed tic incidence data. Because ele-
vated tic counts in the Ticcy genotype population epigeneti-
cally sort into a non-parametric biphasic distribution caused
by the presence within the Ticcy group of between-
individuals (epigenetically) variable but within-individuals
b r a i n r e s e a r c h 1 6 2 9 ( 2 0 1 5 ) 3 8 – 5 350consistent "super (6-fold) ticcers" vs. "elevated (3-fold)
ticcers," the use of an individual repeated-measures drug
design is necessitated, as performed by Nordstrom and
Burton (2002) and herein. In such a design, each subjects'
behavior is tested both with and without drug injection,
which permits drug effects to be tested reliably on such
populations even though the Tg group mean tic count and
standard error will vary between separate drug studies, based
on each Tg group's proportion of "super-ticcers." All data
were expressed as the mean plus standard error of the mean
(SEM) of the number of tics per 15 min, cage midline crossings
per 15 min, or locomotion events per 15 min, occurring during
the videotaped windows of observation.Conﬂict of Interest
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